A settlement provides a massive windfall for Arbutus and Roivant and avoids a worst-case scenario for Moderna.

The administration had cut crucial funding for mRNA-based therapies. The rest of the world might step in and benefit.

This prompts a reassessment of the stock’s value to determine if this represents a genuine opportunity or a potential trap.

WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...

Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...

Integrating AI with advanced robotics to create self-driving labs (SDL) is a promising approach to tackling molecular discovery. A new SDL system, called LUMI-lab, combines large-scale molecular ...

STONY BROOK, NY / ACCESSWIRE / November 9, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has ...

STONY BROOK, NY / ACCESSWIRE / July 13, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it has acquired ...

The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...

PRNewswire/ -- etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one of its key collaborators, Almirall ( ...